BioNexus Gene Lab Corp - Common stock (BGLC)
BGLC moved a median of 0.00% 30 minutes after news, and 0.00% by the close. How BGLC actually reacts to news — the realized, point-in-time move the market made, measured across 123 labeled events over the last three years with zero look-ahead.
BGLC’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 40% | 94 |
| 30-min | 0.00% | 49% | 104 |
| 60-min | 0.00% | 49% | 110 |
| to close | 0.00% | 43% | 120 |
| Middle 50% of BGLC reactions | -2.71% to +2.35% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 123 |
Half of all BioNexus Gene Lab Corp - Common stock news events land between -2.71% and +2.35% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when BGLC moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to BGLC's baseline. Nothing else.
Recent BGLC events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| BioNexus to Build AI Applications for Malaysian Healthcare Under Exclusive CogniAI Licence | Press release | GlobeNewswire | -1.12% | +0.75% | |
| Form 8-K BioNexus Gene Lab Corp For: Oct 05 | SEC filing · Form 8-K | SEC EDGAR | -1.12% | +0.75% | |
| Form 10-Q BioNexus Gene Lab Corp For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -4.91% | -2.39% | |
| BioNexus Advances VitaGuard™ Southeast Asia Rollout Following China Working Visit | Press release | GlobeNewswire | +0.00% | +1.50% | |
| Form 8-K BioNexus Gene Lab Corp For: Jul 28 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +2.27% | |
| Form 8-K BioNexus Gene Lab Corp For: May 29 | SEC filing · Form 8-K | SEC EDGAR | — | +0.00% | |
| BioNexus Gene Lab Corp. Calls for Malaysia–China Biotechnology Cooperation to Move Beyond Trade into Co-Development | Press release | GlobeNewswire | -5.83% | -3.33% | |
| Form 10-Q BioNexus Gene Lab Corp For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +5.56% | |
| Form 10-K BioNexus Gene Lab Corp For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | -5.63% | |
| Form NT 10-K BioNexus Gene Lab Corp For: Dec 31 | SEC filing · Form NT | SEC EDGAR | — | +4.13% | |
| Form 8-K BioNexus Gene Lab Corp For: Mar 11 | SEC filing · Form 8-K | SEC EDGAR | — | +0.00% | |
| BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of the VitaGuard™ MRD Platform | Press release | GlobeNewswire | -2.62% | -4.37% | |
| BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman | Press release | GlobeNewswire | -3.72% | -1.24% | |
| Form 8-K BioNexus Gene Lab Corp For: Feb 23 | SEC filing · Form 8-K | SEC EDGAR | -3.72% | -1.24% | |
| Form 8-K BioNexus Gene Lab Corp For: Jan 28 | SEC filing · Form 8-K | SEC EDGAR | -0.41% | -4.86% | |
| BioNexus Launches Regional Deployment of VitaGuard™ MRD Infrastructure; Positioned to Challenge Legacy Oncology Platforms Across ASEAN’s Multi-Billion Dollar Market | Press release | GlobeNewswire | +1.61% | -1.43% | |
| Form 8-K BioNexus Gene Lab Corp For: Dec 24 | SEC filing · Form 8-K | SEC EDGAR | — | -1.86% | |
| Form 8-K BioNexus Gene Lab Corp For: Dec 19 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +4.27% | |
| BioNexus Gene Lab Corp. Completes Strategic Investment in Fidelion Diagnostics; Secures 15% Equity Stake in Global AI-Oncology Platform and Exclusive Southeast Asian Rights for VitaGuard™ | Press release | GlobeNewswire | -0.16% | +0.23% | |
| Form DEF 14A BioNexus Gene Lab Corp For: Dec 24 | SEC filing · Form DEF | SEC EDGAR | -1.44% | +4.09% | |
| BioNexus Gene Lab Corp. (Nasdaq: BGLC) Secures $500 Million Equity Facility From ARC Group International to Support Expansion of Precision Diagnostics, CDMO Operations, and Therapeutic Commercialization | Press release | GlobeNewswire | +3.49% | +1.16% | |
| Form 8-K BioNexus Gene Lab Corp For: Nov 28 | SEC filing · Form 8-K | SEC EDGAR | +3.49% | +1.16% | |
| BioNexus Gene Lab Corp. (Nasdaq: BGLC) and Fidelion Diagnostics Execute Exclusive Southeast Asia License for VitaGuard™ MRD Platform as Part of Strategic Alliance with Tongshu Gene | Press release | GlobeNewswire | +1.12% | -0.45% | |
| Form 10-Q BioNexus Gene Lab Corp For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.32% | +3.54% | |
| Form PRE 14A BioNexus Gene Lab Corp For: Nov 14 | SEC filing · Form PRE | SEC EDGAR | -1.32% | +3.54% | |
| Form 8-K BioNexus Gene Lab Corp For: Nov 07 | SEC filing · Form 8-K | SEC EDGAR | +1.33% | — | |
| BioNexus Gene Lab Corp. (Nasdaq: BGLC) Announces Strategic Agreements with Fidelion Diagnostics for Southeast Asia MRD Commercialization | Press release | GlobeNewswire | +5.67% | +13.88% | |
| Form 8-K BioNexus Gene Lab Corp For: Nov 12 | SEC filing · Form 8-K | SEC EDGAR | +5.67% | +13.88% | |
| BioNexus Gene Lab Corp. Files $100 Million Shelf Registration and Establishes $20 Million At-the-Market Program to Advance Strategic Growth Opportunities | Press release | GlobeNewswire | +0.00% | +1.35% | |
| Form S-3 BioNexus Gene Lab Corp | SEC filing · Form S-3 | SEC EDGAR | +0.00% | +1.35% | |
| Form 8-K BioNexus Gene Lab Corp For: Oct 20 | SEC filing · Form 8-K | SEC EDGAR | -0.93% | -3.89% | |
| BioNexus Gene Lab Corp Signs Strategic Partnership Term Sheet with BirchBioMed Inc. | Press release | GlobeNewswire | +0.21% | +9.96% | |
| Form 10-Q BioNexus Gene Lab Corp For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | — | |
| Form NT 10-Q BioNexus Gene Lab Corp For: Jun 30 | SEC filing · Form NT | SEC EDGAR | +2.71% | +3.49% | |
| BioNexus Gene Lab Corp. and Fidelion Diagnostics Announce Landmark Alliance—Touted as a new “DeepSeek Moment” in Precision Oncology | Press release | GlobeNewswire | -1.52% | -0.55% | |
| Form 8-K BioNexus Gene Lab Corp For: Jul 30 | SEC filing · Form 8-K | SEC EDGAR | -0.93% | +10.63% | |
| Form 8-K BioNexus Gene Lab Corp For: Jun 17 | SEC filing · Form 8-K | SEC EDGAR | -0.56% | -1.64% | |
| Form 10-Q BioNexus Gene Lab Corp For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -2.06% | |
| BioNexus Gene Lab Corp. Regains Nasdaq Compliance, Signaling Strategic Stability and Growth Readiness | Press release | GlobeNewswire | -6.11% | +2.89% | |
| Form 8-K BioNexus Gene Lab Corp For: Apr 30 | SEC filing · Form 8-K | SEC EDGAR | -10.20% | -3.42% | |
| Form 10-K/A BioNexus Gene Lab Corp For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | — | -1.66% | |
| BioNexus Gene Lab Corp. Files 2024 Annual Report Highlighting Strategic Innovation, Operational Resilience, and Growth Trajectory | Press release | GlobeNewswire | +1.22% | +7.72% | |
| Form 10-K BioNexus Gene Lab Corp For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -1.58% | +4.74% | |
| Form 8-K BioNexus Gene Lab Corp For: Apr 07 | SEC filing · Form 8-K | SEC EDGAR | -0.93% | +0.00% | |
| Form 8-K BioNexus Gene Lab Corp For: Apr 01 | SEC filing · Form 8-K | SEC EDGAR | -0.40% | +15.69% | |
| Form NT 10-K BioNexus Gene Lab Corp For: Dec 31 | SEC filing · Form NT | SEC EDGAR | +1.68% | +14.94% | |
| Form 8-K BioNexus Gene Lab Corp For: Mar 19 | SEC filing · Form 8-K | SEC EDGAR | -1.43% | -0.84% | |
| BioNexus Gene Lab Corp and ML Tech Partner to Enhance Ethereum-focused Treasury Strategy | Press release | GlobeNewswire | +6.08% | +6.86% | |
| Form 8-K BioNexus Gene Lab Corp For: Mar 07 | SEC filing · Form 8-K | SEC EDGAR | -7.09% | -2.72% | |
| BioNexus Gene Lab Corp. Announces Board Approval of Ethereum Treasury Strategy and Release of Strategic Whitepaper | Press release | GlobeNewswire | +9.38% | +6.75% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the BGLC section they belong to.
Where else BGLC is measured.
BGLC earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is BioNexus Gene Lab Corp - Common stock's median reaction calculated?
Every labeled BGLC news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 123 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 49% of BGLC's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does BGLC's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.